🔓
Sign in as a Member to unlock the full view of BBIO. · Full hedge fund list, every line-item carveout, cabinet conflicts, and politicians-trading detail.
Become a Member$29.99/mo already a Member? Sign in →
BBIO

BridgeBio Pharma, Inc.

Sector: pharmaBiotechnologyNASDAQMarket Cap: $14.21B

BridgeBio Pharma is a clinical-stage biopharmaceutical company focused on genetic diseases with minimal political/regulatory footprint and no active lobbying presence.

Next filing → your inbox
Govt Dependence
15/100
Regulatory Density
35/100
Lobbying Intensity
0/100
Political Signal
LOW

BusinessWhat BBIO does

BridgeBio develops therapies for severe genetic diseases through its portfolio of subsidiary companies. Revenue is primarily from research collaborations and milestone payments rather than approved drug sales. The company operates as a biotech holding company with multiple pipeline programs in early-to-mid clinical development.

12 months past · 3 months futureBBIO activity timeline

$93$77$61 DecJan '26FebMarAprMayJunJulAugSepOctNovDecJan '27Feb ↓ PAST — recorded activity ↑ FUTURE — scheduled markups · pending votes TODAY · Nov 17 $90.17 hi $63.30 lo $77.36 CONGRESS 12 INSIDERS 0 13F FUNDS 30 BILLS 28 Gilbert Ray Cisneros (D) · Purchase · 2026-11-02Gilbert Ray Cisneros (D) · Purchase · 2026-10-27Gilbert Ray Cisneros (D) · Sale (Partial) · 2026-09-29Gilbert Ray Cisneros (D) · Purchase · 2026-05-11Gilbert Ray Cisneros (D) · Purchase · 2026-04-29Gilbert Ray Cisneros (D) · Purchase · 2026-03-03Gilbert Ray Cisneros (D) · Purchase · 2026-03-18Gilbert Ray Cisneros (D) · Purchase · 2026-03-19 Viking Global Investors · OPENED $879M · 2026-03-31Viking Global Investors · - $741M · 2026-06-30Two Sigma Investments · + $353M · 2026-06-30Citadel Advisors · + $322M · 2026-06-30D.E. Shaw & Co. · - $273M · 2026-06-30Citadel Advisors · + $252M · 2026-03-31Two Sigma Investments · OPENED $232M · 2026-03-31D.E. Shaw & Co. · OPENED $189M · 2026-03-31Point72 Asset Management · + $114M · 2026-06-30D.E. Shaw & Co. · + $107M · 2026-03-31Renaissance Technologies · + $64M · 2026-06-30Renaissance Technologies · + $56M · 2026-09-30Millennium Management · + $50M · 2026-06-30Citadel Advisors · + $49M · 2026-06-30Millennium Management · - $47M · 2026-03-31Millennium Management · + $44M · 2026-03-31Bridgewater Associates · + $33M · 2026-06-30Millennium Management · + $31M · 2026-06-30Renaissance Technologies · OPENED $27M · 2026-03-31Citadel Advisors · OPENED $23M · 2026-03-31Citadel Advisors · - $20M · 2026-06-30Bridgewater Associates · OPENED $19M · 2026-03-31AQR Capital Management · holds $12M · 2026-06-30AQR Capital Management · OPENED $12M · 2026-03-31Point72 Asset Management · OPENED $4M · 2026-03-31Millennium Management · - $2M · 2026-03-31Renaissance Technologies · - $1M · 2026-03-31Millennium Management · OPENED $1M · 2026-03-31Millennium Management · - $1M · 2026-06-30Millennium Management · - $1M · 2026-06-30 HR.2001 · passed_one · 2026-07-21 MARKUP · Senate Veterans' Affairs · 2026-11-18MARKUP · Senate Health, Education, Labor, and Pensions · 2026-11-18MARKUP · Senate Veterans' Affairs · 2026-11-18
Congress
buy sell
Insider · Form 4
open-market buy
Hedge fund · 13F
opened + added − trimmed closed holds
Bills
past action (this ticker) upcoming markup (sector) ★ carveout (this ticker)
250 trading days · 8 congressional trades shown · 0 insider buys · 30 13F filings · 1 past bill actions · 3 upcoming markups

Executive Branch ConflictsBBIO held by Trump-administration officials

1 cabinet/senior official reported BBIO positions in OGE Form 278 disclosures across 1 filings.

Lifetime Government AwardsBBIO federal contracts

BBIO doesn't hold direct federal contracts.

Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.

Smart Money · 13F HoldingsHedge funds holding BBIO

$2.06B
Total BBIO held by tracked 13F funds
16
Funds with BBIO positions
Viking Global Investors $741M -16% 2 overlap 2026-06-30
Two Sigma Investments $353M +17817% 2 overlap 2026-06-30
Citadel Advisors $322M +28% 2 overlap 2026-06-30
D.E. Shaw & Co. $273M -94% 2 overlap 2026-06-30
Point72 Asset Management $114M +3147% 2 overlap 2026-06-30
Renaissance Technologies $56M +1362% 3 overlap 2026-09-30
Millennium Management $50M +6% 2 overlap 2026-06-30
Citadel Advisors $49M +570% 2 overlap 2026-06-30
8 more 13F positions tracked · quarterly delta charts available in member dashboard

Politicians Trading BBIOMembers of Congress with recent BBIO positions

1 politicians traded BBIO across 12 disclosed transactions totaling $96K (last 730 days). Greed score = composite of trade frequency, volume & recency across the politician's entire history (not just BBIO). 0-30 LOW · 30-60 MID · 60+ HIGH.

Congressional TradesWho in Congress is trading BBIO

2026-11-02 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2026-10-27 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2026-09-29 Gilbert Ray Cisneros D-California · house Sale (Partial) $1,001 - $15,000
2026-05-11 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2026-04-29 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2026-03-03 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2026-03-18 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2026-03-19 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2025-09-22 Gilbert Ray Cisneros D-California · house purchase $1,001 - $15,000
2025-09-22 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2025-08-08 Gilbert Ray Cisneros D-California · house purchase $1,001 - $15,000
2025-08-08 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
12+ trades on file · most recent 2026-11-10

Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock

Stock awards & option exercises

8
option exercises · $9.7M
For BBIO, executives receive stock primarily as compensation rather than via open-market purchases — typical for established large-cap firms.

Bills Affecting BBIOLive legislation impacting this stock

Political ProfileWhere BBIO sits in Washington

Clinical-stage biotech with no lobbying activity and minimal regulatory exposure. Stock movement driven by clinical trial data and financing events, not policy.

Regulatory ExposureThreats & opportunities

Regulatory threats

  • FDA clinical trial requirements tightening
  • rare disease reimbursement pressure

Regulatory opportunities

  • Orphan drug tax credit expansion
  • accelerated approval pathway utilization
Member intelligence layer

Live signals + predictions for BBIO — for Founders

The free page above gives you the public record. Members see the real-time intelligence layer on top of it:

Become a Founder · $29.99/mo Locked rate forever · cancel anytime

Frequently AskedAbout BBIO & political exposure

Does BridgeBio Pharma, Inc. (BBIO) hold federal contracts?
No direct prime contracts reported in USASpending.gov for BridgeBio Pharma, Inc.. Companies in the semiconductor and AI hardware sectors often sell to the federal government via prime contractors and cloud resellers (Microsoft Azure, AWS, Lockheed Martin systems integration) rather than as direct primes.
Which Trump cabinet officials own BBIO stock?
1 Trump cabinet members or senior White House staff have disclosed holdings in BBIO on their OGE 278 financial disclosures, including Donald J. Trump. See the Cabinet Conflicts panel for details.
Has Congress traded BBIO stock?
12 congressional trades by 1 unique members of Congress, most recently on 2026-11-02. See the Congressional Trading panel for politician-by-politician breakdown.
What is BBIO political risk profile?
Government dependence: 15/100. Lobbying intensity: 0/100. Political signal: low.
How does GovGreed track BBIO political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. BBIO data is updated daily from these official federal sources.